Nf-kb Signal Path-Manipulated Dendritic Cells

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a method to manipulate dendritic cells (a key type of immune cell) by introducing mutated proteins into their NF-κB signaling pathway via RNA transfection. By altering the activity of this pathway, the dendritic cells can be programmed to produce specific immune responses, such as enhancing immunity (e.g., against tumors or infections) or inducing immune tolerance (e.g., to suppress autoimmune diseases or allergies). The manipulated dendritic cells can then be used in pharmaceutical preparations for immunotherapy, vaccines, or ex vivo expansion of specific immune cells.

Use CasesContent extracted from patent full text and abstract with AI.

• Immunotherapy for cancer patients, using manipulated dendritic cells to induce strong anti-tumor immune responses.
• Therapeutic vaccines for infectious diseases, such as HIV, by stimulating effective immune responses via customized dendritic cells.
• Treatment or prevention of autoimmune diseases, by generating immune tolerance using specific types of manipulated dendritic cells.
• Allergy treatment, by promoting immune tolerance to allergens via modified dendritic cells.
• Ex vivo expansion of CD8+ T cells for adoptive cell transfer therapies in cancer or other diseases.
• Prevention or reduction of transplant rejection by inducing tolerance using modified dendritic cells.

BenefitsContent extracted from patent full text and abstract with AI.

• Avoids permanent genetic modification since RNA transfection is transient and does not alter the genome.
• Reduces risks associated with viral vectors (e.g., insertional mutagenesis and adverse immune responses) commonly used in gene therapy.
• Enables precise control of dendritic cell function to stimulate or suppress immune responses depending on clinical needs.
• Can enhance the production of key cytokines (e.g., IL-12p70 for immunity, IL-10 for tolerance) for tailored therapy.
• Facilitates development of personalized therapies using patient-derived cells (autologous approach), reducing rejection risk.
• Method is adaptable for different diseases by simply changing the antigen payload or the activation state of the dendritic cells.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to dendritic cells, the NF-KB signal path of which has been manipulated by RNA transfection, to the manufacture thereof and to use thereof.